Tirzepatide and Pregnancy: Safety, Risks, and What to Do

Most people who use tirzepatide for weight loss are women between 25 and 50. Many are at a stage of life where pregnancy is possible, planned, or being considered. That makes one question come up constantly: is it safe to take tirzepatide while pregnant, or while trying to get pregnant?

The direct answer is no. Tirzepatide is contraindicated during pregnancy and should be stopped well before you try to conceive. But that one-sentence answer leaves out a lot of important context. It misses the timing question, the fertility conversation, the contraception piece, and what to do if you unexpectedly become pregnant while on this medication.

This article covers all of it, clearly and honestly.

*This article is for educational purposes only and does not constitute medical advice. Compounded tirzepatide is not FDA-approved. Always consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

Is Tirzepatide Safe During Pregnancy?

No. Tirzepatide is not considered safe to use during pregnancy based on current evidence. The FDA prescribing information for Mounjaro and Zepbound states clearly that tirzepatide should be discontinued when pregnancy is confirmed or planned.

The concern comes from preclinical animal studies. In reproductive toxicology studies in rats and rabbits, tirzepatide caused adverse fetal developmental outcomes at doses comparable to human therapeutic levels. Findings included increased fetal abnormalities, reduced fetal body weight, and skeletal variations. These results triggered the standard precautionary language in both prescribing information documents: based on animal data, tirzepatide may cause fetal harm when administered to a pregnant woman.

There are no adequate, well-controlled studies of tirzepatide in pregnant humans. This is not unusual for medications approved in the past several years. Pregnant women are routinely excluded from clinical trials. The absence of human data does not mean the drug is safe in pregnancy. It means we do not have the evidence to know, and given the animal signals, the appropriate clinical position is to avoid use entirely.

Tirzepatide's dual mechanism (GIP and GLP-1 receptor agonism) raises a natural question: does activating two receptors create different reproductive risks compared to GLP-1-only medications like semaglutide? Based on current preclinical evidence, the risk profile appears similar across the class. Both mechanisms were present in the animal studies, and the developmental concerns seen with tirzepatide are consistent with what has been observed with other GLP-1 receptor agonists. However, tirzepatide has been commercially available for a shorter period than older GLP-1 medications, so the total body of reproductive safety data is still accumulating.

---

Why You Need to Stop Tirzepatide Before Conceiving

The FDA prescribing information for Mounjaro and Zepbound recommends stopping tirzepatide at least 2 months before a planned pregnancy. This guidance has a clear pharmacological rationale.

Weekly injectable tirzepatide has a half-life of approximately 5 days. This is notably long for an injectable medication, though slightly shorter than semaglutide's approximate 7-day half-life. Because of this extended half-life, tirzepatide takes considerably longer to clear your system than most medications. Following standard pharmacokinetic calculations, full elimination takes roughly 5 weeks after the last dose.

The 2-month recommendation builds a safety margin on top of that clearance window. The goal is to ensure that by the time conception occurs, tirzepatide levels are undetectable and the critical early weeks of embryonic development occur without any drug exposure.

Early fetal development, particularly the first 8 to 12 weeks of pregnancy, is when organ formation happens. This is when the embryo is most vulnerable to anything that could interfere with normal cellular growth and differentiation. The 2-month washout before conception is designed to keep that window clean.

If you are considering pregnancy in the next several months, this timeline has real practical implications. You need to have a conversation with your prescribing provider now, not after a positive pregnancy test.

---

What Happens If You Become Pregnant While Taking Tirzepatide?

Stop the medication immediately and contact your healthcare provider the same day.

This is not a cause for panic, but it requires immediate action. Early discontinuation limits the duration of any fetal exposure. Your provider will advise on next steps, which typically include confirming the pregnancy, establishing prenatal care, and notifying your OB or midwife about prior medication use.

If you have been using tirzepatide and discovered a pregnancy in the early weeks, the exposure window may have been limited. That does not guarantee there is no risk, but earlier discontinuation is meaningfully better than continuing the medication into the second or third trimester.

Do not wait for your next scheduled appointment. Call your provider as soon as you have a positive test.

There is also a pregnancy registry. Eli Lilly maintains a pregnancy exposure registry for tirzepatide to collect safety data on pregnancies where exposure occurred. You or your provider can enroll by calling 1-800-LillyRx (1-800-545-5979). Contributing to that registry helps build the evidence base that does not yet exist for this medication in human pregnancy.

---

Tirzepatide, Weight Loss, and Fertility: The PCOS Connection

Here is where the picture becomes more nuanced. While tirzepatide is contraindicated during pregnancy, its use before conception may actually improve fertility for a significant subset of women, particularly those with polycystic ovary syndrome (PCOS).

PCOS affects approximately 8 to 13 percent of women of reproductive age and is one of the most common causes of ovulatory infertility. Insulin resistance and excess adipose tissue drive much of the hormonal disruption in PCOS, including elevated androgens, irregular cycles, and anovulation. Weight loss consistently improves these parameters, even modest weight loss of 5 to 10 percent of body weight.

The connection between weight loss and fertility improvement is well established. A foundational study published in Human Reproduction showed that modest weight reduction in obese anovulatory women resulted in resumption of ovulation and significantly improved pregnancy rates without fertility medications. (Clark AM et al., Hum Reprod. 1995;10(10):2705-12. PMID: 8567799)

GLP-1 receptor agonists as a class have shown reproductive hormone improvements in women with PCOS beyond what weight loss alone would predict. Research published in Current Diabetes Reports found that GLP-1 receptor agonists improved ovulatory function and reduced androgen levels in women with PCOS, with effects beyond those attributable to weight reduction alone. (Lamos EM et al., Curr Diab Rep. 2017;17(10):84. PMID: 28836148)

Tirzepatide's dual mechanism adds a relevant layer here. GIP receptors are expressed in adipose tissue, and tirzepatide's action at these receptors appears to redistribute fat away from visceral depots. In PCOS, visceral adiposity is a key driver of insulin resistance and the downstream hormonal dysregulation that impairs ovulation. Tirzepatide's effects on body composition may therefore be particularly relevant for this population.

What this means practically: if you are using tirzepatide for weight loss and have PCOS or obesity-related anovulation, your fertility may improve during treatment. This is medically positive and important to plan for. Improved fertility while on tirzepatide means an unintended pregnancy is more likely than it might have been before treatment. Use reliable contraception if pregnancy is not your current goal.

---

Contraception While on Tirzepatide: What You Need to Know

Because tirzepatide can improve fertility in women who previously had irregular cycles or anovulation, effective contraception during treatment is essential if you are not actively trying to conceive.

Two points are worth understanding about contraception and tirzepatide.

First, the general principle: if pregnancy is not your goal during tirzepatide treatment, use reliable contraception. The same applies during the 2-month washout period before attempting conception. Consult your provider about the contraceptive method that fits your situation.

Second, a specific note on oral contraceptives: tirzepatide slows gastric emptying, which can theoretically affect the absorption of oral medications, including combined oral contraceptives. Eli Lilly conducted pharmacokinetic studies evaluating this interaction for tirzepatide. Those studies found that tirzepatide did not meaningfully alter the bioavailability of oral contraceptive hormones in study participants. However, individual variation exists, and the prescribing information recommends that patients using oral contraceptives who start tirzepatide switch to a non-oral contraceptive method or add a barrier method for at least 4 weeks after starting tirzepatide and after each dose escalation.

This is a specific recommendation from the Mounjaro and Zepbound prescribing information. If you use oral contraceptives, review this guidance with both your GLP-1 prescriber and your gynecologist. Long-acting reversible contraceptives (IUDs, implants) avoid the oral absorption concern entirely if that is a preference.

---

Planning a Pregnancy After Tirzepatide

Stopping tirzepatide before conception does not mean abandoning the progress you have made. It means transitioning thoughtfully.

A few practical considerations for that transition:

Timing and weight stability. When you stop tirzepatide, appetite typically returns as the medication clears. Some weight regain is common, particularly in the weeks immediately following discontinuation. Discussing a maintenance strategy with your provider before stopping gives you the best foundation for the washout period and early pregnancy. Some providers recommend a dietary and behavioral maintenance plan to bridge the gap.

Prenatal nutrition. Pregnancy nutritional needs are different from weight loss nutritional needs. Begin prenatal vitamins (particularly folic acid, at least one month before conception) before you start trying. Your OB or midwife will have specific recommendations.

Discussing your history. When you establish prenatal care, disclose your full medication history, including tirzepatide use and the approximate stop date. This context helps your care team assess your pregnancy appropriately.

No rush required. Nothing in the current evidence suggests that having used tirzepatide for weight loss creates ongoing risk to a future pregnancy, provided the washout period has been completed. The 2-month window exists to eliminate that concern, and once it has passed, prior tirzepatide use is not expected to affect pregnancy outcomes.

---

How Prescriva Handles Pregnancy Situations

Prescriva does not prescribe tirzepatide or any GLP-1 medication to patients who are currently pregnant. Every intake process includes questions about current pregnancy and pregnancy plans.

If you become pregnant while receiving GLP-1 treatment through Prescriva's affiliated network, contact your prescribing provider immediately. The provider will discontinue the prescription and advise on next steps. You will not be left without support during that transition.

If you are planning a pregnancy, raise that directly with your provider during your next check-in. A planned approach, including establishing a discontinuation timeline and building a maintenance strategy, is better for you than an abrupt stop with no plan.

---

Bottom Line

Tirzepatide is not appropriate to use during pregnancy, and current FDA guidance recommends stopping at least 2 months before attempting to conceive. This timeline accounts for the drug's half-life of approximately 5 days and ensures embryonic development is not exposed to the medication during the critical early weeks of organ formation.

If you become pregnant while taking tirzepatide, stop immediately and contact your provider that day. You can also contact Eli Lilly's pregnancy exposure registry at 1-800-LillyRx (1-800-545-5979) to contribute to the safety data for this medication.

The fertility picture is more complex. For women with PCOS or obesity-related cycle irregularities, tirzepatide-facilitated weight loss may improve fertility. That is a real clinical benefit and a real reason to use contraception reliably during treatment if pregnancy is not your goal. The specific guidance on oral contraceptives and tirzepatide is also worth reviewing with your provider.

The 2-month washout, reliable contraception during treatment (with attention to the oral contraceptive interaction guidance), and a planned transition conversation with your provider cover the key bases. None of this requires you to choose between treating your weight and eventually having children. It requires planning and honest communication with your care team.

---

*This article does not constitute medical advice. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, equivalent to, or interchangeable with Mounjaro or Zepbound. Results vary and are not guaranteed. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Blue Oak Services LLC dba Prescriva is a management services organization; it does not practice medicine or make clinical decisions. All care is delivered by independently licensed healthcare providers. Consult your licensed healthcare provider before starting, stopping, or changing any medication.*

---

Sources

1. Clark AM, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Hum Reprod.* 1995;10(10):2705-12. PMID: 8567799.

1. Lamos EM, et al. Mechanisms and effects of glucose-lowering drugs on polycystic ovary syndrome. *Curr Diab Rep.* 2017;17(10):84. PMID: 28836148.

1. Ozbek L, et al. Safety of GLP-1 and dual GLP-1/GIP receptor agonists in preconception, pregnancy, and the postpartum period. *Diabetes Obes Metab.* 2026. PMID: 41885132.